Hepatitis C telemedicine approach for opioid users receives award
A program using a telemedicine approach to treat hepatitis C in people with opioid use disorder that resulted in the cure of more than…
Hepatitis
Hepatitis B gene-editing therapy PBGENE-HBV shows early promise
A single dose of Precision BioSciences’ investigational gene-editing therapy PBGENE-HBV was well tolerated and showed early signs of antiviral activity among three adults with…
Dosing complete in Phase 2b trial of AHB-137 for hepatitis B
A Phase 2b clinical trial testing AusperBio’s investigational therapy AHB-137 in people with chronic hepatitis B has completed dosing and is now unblinded,…
Virtual clinic for liver diseases opens to US patients
A virtual clinic for liver diseases, including hepatitis, has begun treating patients. The LiverRight Hepatology Clinic offers same-week video visits to adults who…
HBV vaccine birth dose not tied to premature babies’ lung disease risk
Babies born extremely prematurely who were given a dose of the hepatitis B virus (HBV) vaccine within a day of being born were not…
FDA grants breakthrough designation to hepatitis D treatment
The U.S. Food and Drug Administration (FDA) has granted breakthrough therapy designation to brelovitug, a hepatitis D treatment that’s being developed by Bluejay…
Trial of HBV treatment candidate now enrolling final patient group
Virion Therapeutics has announced that it’s completed enrollment for the first two groups of adults with chronic hepatitis B virus (HBV) infection in…
ABI-4334 shows promise in hepatitis B Phase 1b trial: Data
Oral therapy ABI-4334 shows potent antiviral activity in adults with chronic hepatitis B virus (HBV) infection, according to interim data from an ongoing Phase…
Hepatitis D treatment combo granted new designations in US, EU
Tobevibart and elebsiran, an experimental treatment combination that Vir Biotechnology is developing for chronic hepatitis D, has been awarded both breakthrough therapy designation…
Bemnifosbuvir-ruzasvir combo clears HCV for most in Phase 2 trial
A two-month course of an oral antiviral treatment combination of bemnifosbuvir and ruzasvir was well tolerated and led to sustained clearance of the…
Recent Posts
- Rezdiffra reduces scarring in MASH with compensated cirrhosis: Trial
- 6 JAG1, NOTCH2 gene mutations ID’d as likely cause of Alagille
- To test or not to test for PFIC3? Our families face the question.
- Hepatitis C telemedicine approach for opioid users receives award
- Seladelpar conditionally approved in European Union to help treat PBC